摘要
目的研究门冬氨酸钾镁联合胺碘酮治疗阵发性心房颤动的临床疗效。方法入选180例阵发性心房颤动患者,随机分为两组,每组90例,其中对照组予以胺碘酮治疗,研究组采用门冬氨酸钾镁联合胺碘酮治疗,治疗随访1年后,比较两组相关临床资料。结果治疗6个月和12个月后,两组的房颤发作次数及房颤发作持续时间均较治疗前明显减少(P<0.05),且研究组较对照组减少幅度更大(P<0.05)。治疗6个月后和12个月后,研究组的窦性心律维持率均较对照组明显升高(P<0.05)。对照组和研究组中,分别有2例和3例出现严重的窦性心动过缓,均无其他严重不良反应发生。结论门冬氨酸钾镁联合胺碘酮治疗心房颤动具有较好的临床效果,不仅可以减少其发作次数,缩短发作持续时间,提高窦性心律维持率,而且不增加不良反应。
Objective To study the effects of potassium magnesium aspartate combined with amiodarone on treatment of paroxysmal atrial fibrillation （PAF）. Methods A total of 180 PAF patients were selected and randomly divided into two groups（n=90, respectively）： the control group was treated with amiodarone and the study group with potassium magnesium aspartate combined with amiodarone. After one-year follow-up, the relevant clinical data of the two groups were compared. Resttlls The number and duration of AF episodes in the two groups 6 and 12 months after the treatment were much lower and shorter than those before the treatment （P 〈 0.05）, and the decrease in the study group was more obvious than that in the control group （P 〈 0.05）. 6 and 12 months after the treatment, the sinus rhythm maintenance rate in the study group was much higher than that in the control group（P 〈 0.05）. There were only two and three cases of severe sinus bradycardia in the control group and the study group respectively, no other severe adverse reactions occurred. Conclusion The treatment of AF with potassium magnesium aspartate and amiodarone has good clinical effects. It can not only reduce the number and duration of AF episodes and improve the sinus rhythm maintenance rate, but also lower the incidence of adverse reactions.
出处
《西南国防医药》
CAS
2016年第9期981-983,共3页
Medical Journal of National Defending Forces in Southwest China
